@article{21837b8317bc41ac9b454dec266dfe13,
title = "Patent foramen ovale transcatheter closure device thrombosis",
abstract = "The role of patent ovale (PFO) in patients with cryptogenic stroke (stroke of unknown cause) remains controversial, although an association seems likely in younger patients with septal anuerysms and PFO. The mechanism of cryptogenic embolism via right-to-left shunt across the PFO. The available options for treatment include medical therapy with antiplatelet or anticoagulant therapy or closure of the PFOP closure devices. We describe 2 cases of bilateral device thrombosis associated with the use of a transcatheter PFO closure device (CardioSEAL). To our knowledge, only 1 other case thrombvosis associated with use of this device has been reported.",
keywords = "APC-R = activated protein C resistance, ASD = atrial septal defect, DVT = deep venous thrombosis, INR = international normalized ratio, PFO = patent foramen ovale, TEE = transesophageal echocardiography, TIA = transient ischemic attack, TTE = transthoracic echocardiography",
author = "Nkomo, {Vuyisile T.} and Pierre Theuma and Maniu, {Calin V.} and Krishnaswamy Chandrasekaran and Miller, {Fletcher A.} and Schaff, {Hartzell V.} and Petty, {George W.} and Miller, {Todd D.}",
note = "Funding Information: No precise guidelines exist for the management of PFO in patients who present with cryptogenic stroke. Studies regarding the relevance of PFO in patients with cryptogenic stroke report conflicting outcomes. 17 Data supporting closure of PFO include a higher risk of stroke recurrence in patients with such a disorder compared with patients without it, especially when it is associated with an atrial septal aneurysm. 18 Current methods of closing PFO involve open heart surgery or transcatheter techniques. Both methods have been shown to be effective 2,3,12,15,19 ; however, no prospective randomized trials exist comparing the 2 methods. Medical therapy with antiplatelet or anticoagulant drugs to prevent recurrent neurologic events is an alternative to PFO closure, 20,21 and a multicenter study funded by the National Institutes of Health is under way to assess stroke recurrence in patients randomly assigned to receive anticoagulant or aspirin therapy. ",
year = "2001",
month = oct,
doi = "10.4065/76.10.1057",
language = "English (US)",
volume = "76",
pages = "1057--1061",
journal = "Mayo Clinic proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "10",
}